Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Xiaomi Q2 Revenue Hits $16.2B, Up 9.9% QoQ as EV Deliveries Reach 104K

According to Xiaomi on August 19, the company's second-quarter 2026 revenue rose 9.9% quarter on quarter to 108.9 billion yuan ($16.2 billion). Adjusted net profit increased 2.4% to 6.2 billion yuan ($920 million). Smartphone shipments remained in the global top three for a 24th consecutive quarter,
GateNews·08-19 04:55
Xiaomi Q2 Revenue Hits $16.2B, Up 9.9% QoQ as EV Deliveries Reach 104K

KOSPI Slides Over 6% on Aug 19, Steady Near 6,500 Amid Selling Pressure

According to Korea Exchange, KOSPI tumbled over 6% in early trading on Aug 19 afternoon but pared losses as selling by foreign investors and institutions continued, with the index trading around the 6,500 level. Retail investors, meanwhile, purchased over 4 trillion Korean won in net inflows,
GateNews·08-19 04:37
KOSPI Slides Over 6% on Aug 19, Steady Near 6,500 Amid Selling Pressure

Yuyu Pharma's Pan-KRAS Inhibitor ABSK211 Receives NMPA IND Approval

According to an announcement by Yuyu Pharma (HKEX: 02256) today (August 19), China's National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for ABSK211, an oral, potent pan-KRAS inhibitor targeting advanced solid tumors with KRAS mutations. This approval follows the drug's FDA IND clearance on July 8. Yuyu Pharma will initiate an open-label Phase I clinical trial to evaluate ABSK211's safety, tolerability, efficacy, and pharmacokinetics in pat
ABBISKO-B-0.66%
GateNews·08-19 04:36
Yuyu Pharma's Pan-KRAS Inhibitor ABSK211 Receives NMPA IND Approval